Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
复制标题
DOI：
--
复制
发表时间：
2018-05
影响因子：
3.7
通讯作者：
M. Ogawa-Momohara;Y. Muro;T. Mitsuma;M. Katayama;K. Yanaba;M. Nara;Masao Kakeda;M. Kono;M. Akiy
中科院分区：
文献类型：
--
作者：
M. Ogawa-Momohara;Y. Muro;T. Mitsuma;M. Katayama;K. Yanaba;M. Nara;Masao Kakeda;M. Kono;M. Akiy
转录中间因子1γ（TIF 1 γ）蛋白被认为是促进细胞分化的肿瘤抑制因子。针对TIF 1 γ的自身抗体与皮肌炎（DM）相关的癌症具有强的临床相关性。本研究旨在鉴定患有DM的抗TIF 1 γ抗体阳性成年患者中癌症的临床特征。方法本回顾性分析涵盖了2003年至2016年期间访问名古屋大学医院或合作医疗中心的160名成年DM患者。ELISA法检测血清中抗TIF 1 γ抗体及其他肌炎特异性自身抗体。根据对病历的审查，根据国际癌症控制联盟的恶性肿瘤TNM分类对癌症进行分期，并根据分期分类将癌症分为“晚期”和“非晚期”两组。结果160例患者中有41例（26%）患有癌症。抗TIF 1 γ阳性患者的发生率显著高于抗TIF 1 γ阴性患者（23/34=68% vs. 18/126= 14%，p<1x 10 -6）。抗TIF 1 γ阳性的癌症患者在“晚期”组中比在“非晚期”组中更常见（21/23=91% vs. 9/18= 50%，p<0.0046）。抗TIF 1 γ阳性患者中DM诊断与癌症诊断之间的间隔显著短于抗TIF 1 γ阴性患者（p=0.047）。结论抗TIF 1 γ抗体不仅与DM患者的恶性肿瘤密切相关，而且抗TIF 1 γ阳性DM患者的癌症也明显比抗TIF 1 γ阴性患者更晚期。在这种情况下，癌症经常被发现接近糖尿病诊断的时间。
OBJECTIVES Transcription intermediary factor 1γ (ΤΙF1γ) protein is known as a tumour suppressor that promotes cellular differentiation. Autoantibodies to ΤΙF1γ have a strong clinical association with cancers associated with dermatomyositis (DM). This study aims to identify the clinical characteristics of cancers in anti-ΤΙF1γ antibody-positive adult patients with DM. METHODS This retrospective analysis covered 160 adult DM patients who visited Nagoya University Hospital or collaborating medical centres between 2003 and 2016. Anti-TIF1γ antibody and other myositis-specific autoantibodies were detected by ELISA. Based on a review of medical charts, the cancers were staged according to the TNM Classification of Malignant Tumours of the Union for International Cancer Control and were divided into the two groups of "advanced" or "non-advanced" according to the stage classification. RESULTS Forty-one of the 160 (26%) patients had cancer. The incidence was significantly higher in the anti-TIF1γ-positive patients than in the anti-TIF1γ-negative patients (23/34=68% vs. 18/126=14%, p<1x10-6). Anti-TIF1γ-positive patients with cancer were found more frequently in the "advanced" group than in the "non-advanced" group (21/23=91% vs. 9/18=50%, p<0.0046). The intervals between DM diagnosis and cancer diagnosis were significantly shorter in the anti-TIF1γ-positive patients than in the anti-TIF1γ-negative patients (p=0.047). CONCLUSIONS Not only did anti-TIF1γ antibodies correlate strongly with malignancy in DM patients, but cancers were also significantly more advanced in anti-TIF1γ-positive DM patients than in anti-TIF1γ-negative patients. Cancers in such cases were very frequently found close to the time of the DM diagnosis.